SHS Gesellschaft für Beteiligungsmanagement mbH
14. March 2022 - Newsletter, Portfolio News

CoreMedic’s ChordArt™ mitral valve repair implant proves effectiveness in two-year study

Mitral valve regurgitation (leakage) is one of the very common heart diseases. It is estimated that around 25 million patients worldwide suffer from it. CoreMedic GmbH has developed the ChordArt™ mitral valve repair system, a device for the safe repair of the mitral valve. In a broad, two-year patient study, the ChordArt™ system has now been able to prove its effectiveness and safety, as shown by the data published in the Journal of Thoratic and Cardiovascular Surgery on 29.10.2021 as a PreProof study.

More information: